Anthropic has debuted Claude Science, a new AI tool designed as a workbench for scientists in drug discovery, available locally on Linux or macOS or through a remote machine. The application, currently in beta testing, unifies fragmented tools and databases across the drug discovery workflow, integrating resources like PubMed, Jupyter and R to allow multi-step research, literature analysis, and generation of scientific artefacts such as 3D protein structures. Claude Science includes more than 60 functions for genomics, structural biology, proteomics and cheminformatics, assisting tasks like CRISPR screen design, single-cell RNA sequencing analysis and 3D protein structure rendering. This launch follows Anthropic's release of Claude for Life Sciences in October 2025 and comes amid the US' call to lift its export ban on Anthropic's advanced AI tools. Anthropic is also initiating an internal drug discovery programme focused on "neglected" diseases. Competitors like OpenAI and Google are debuting similar tools, while Anthropic partnered with Bristol Myers Squibb to roll out Claude to over 30,000 employees in May 2026. OpenAI has forged pacts with Novo Nordisk, Eli Lilly, Moderna and Sanofi. The total value of AI partnerships in the pharma space took a 120% uptick year-on-year between 2024 and 2025, according to GlobalData's Pharmaceutical Intelligence Center.